Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YC4F
|
|||
| Former ID |
DIB005426
|
|||
| Drug Name |
K-828-AB
|
|||
| Synonyms |
GABA transaminase inhibitor (oral, dementia), Kowa
Click to Show/Hide
|
|||
| Indication | Dementia [ICD-11: 6D80-6D86] | Phase 2 | [1] | |
| Company |
Kowa Co Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | GABA transaminase (ABAT) | Target Info | Inhibitor | [2] |
| BioCyc | GABA shunt | |||
| Valine degradation | ||||
| Beta-alanine degradation | ||||
| 4-aminobutyrate degradation | ||||
| KEGG Pathway | Alanine, aspartate and glutamate metabolism | |||
| Valine, leucine and isoleucine degradation | ||||
| beta-Alanine metabolism | ||||
| Propanoate metabolism | ||||
| Butanoate metabolism | ||||
| Metabolic pathways | ||||
| GABAergic synapse | ||||
| Panther Pathway | Aminobutyrate degradation | |||
| Pyrimidine Metabolism | ||||
| Gamma-aminobutyric acid synthesis | ||||
| Pathwhiz Pathway | Aspartate Metabolism | |||
| Glutamate Metabolism | ||||
| Beta-Alanine Metabolism | ||||
| Valine, Leucine and Isoleucine Degradation | ||||
| Propanoate Metabolism | ||||
| WikiPathways | GABA synthesis, release, reuptake and degradation | |||
| Alanine and aspartate metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Kowa Co Ltd. | |||
| REF 2 | Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.